ASSAYED, NOT ASSERTEDSee Sample COA->
PeptideSource B2B RESEARCH MATERIALS
Menu
CatalogPurchase ListQualityAbout
EN中文
WhatsApp supportLog inCreate account
← Back to catalog

peptide research material

Semaglutide

Metabolic & GLP-1
Semaglutide

Purchase options

Semaglutide purchase details

From $2.05/vial · In stock

Lowest published volume-tier equivalent. View pack prices and order tiers below.

Specifications7 SKUs

2mg*10vials

SEMAGLUTIDE-2MG-10VIALS

≥99%

$38.20Tier 1 / 10 vials

MOQ: 1 10 vials

Order T1$200+$38.20
Order T2$2,000+$28.65
Order T3$5,000+$23.40
Order T4$10,000+$20.53

Worldwide shipping to most destinations. Contact us on WhatsApp for special destinations.

Orders are normally prepared for dispatch the next business day. Contact us on WhatsApp for special handling or timing requirements.

Ask on WhatsAppEmail purchase supportHow it works? View a Sample Verification Page

For metabolic & glp-1 buyers, PeptideSource uses Semaglutide as a document-led sourcing record. The identity layer covers CAS 910463-68-2, formula C187H291N45O59, 4114 Da molecular weight; the commercial layer covers sku coverage includes 10mg*10vials · 15mg*10vials · 20mg*10vials · 2mg*10vials · 3 more sizes, MOQ, order-tier pricing, and repeat-supply fit. COA, HPLC, MS, SDS, storage, and batch notes remain the main procurement evidence.

Buyer fit

Who buys this, and why

Semaglutide is listed for qualified B2B buyers reviewing metabolic and incretin-pathway research-material sourcing. Procurement teams should compare incretin, amylin, metabolic-pathway, SKU ladder, and batch-file readiness while keeping the page focused on research-material sourcing rather than personal-use, dosing, treatment, or outcome guidance.

Category: Metabolic & GLP-1. GLP-1, GIP, GCG, amylin, lipolytic, and metabolic-pathway materials for commercial sourcing review.

Specifications

Procurement-ready product data

CAS
910463-68-2
Molecular formula
C187H291N45O59
Molecular weight
4114 Da
Appearance
Lyophilized powder or supplied format listed on batch COA
Purity / identity
≥99%
Common vial sizes
10mg*10vials · 15mg*10vials · 20mg*10vials · 2mg*10vials · 3 more sizes
Storage
Store according to the batch COA and product handling note.

Batch Quality Verification

See how PeptideSource verifies a lot before document review.

Sample COA format, lot-code conventions, and the current-batch matching workflow are summarized below. Sample values are clearly marked as demo records; live HPLC/MS and release files are matched by QA.

Sample verification card

PS-SEM-2606-002

Public demo page showing the PeptideSource COA format, QA status, and PDF access pattern.

Current batch request

Matched by SKU + lot ID

Live order documents are supplied after QA confirms the exact product, SKU, and available lot.

Example lot-code format

PS-SEM-2606-270

Format example only. Real batch IDs are assigned from production and release records.

QA review window

4-13 business hours

Typical document-matching window for qualified procurement requests, subject to current batch status.

Laboratory Planning Tool

Plan vial mass, volume, and inventory notes.

Open the calculator as a procurement planning aid for vial mass, diluent-volume records, and target concentration notes. It is not a human-use protocol, administration guide, or clinical recommendation.

Open laboratory calculator

Priority sourcing brief

Semaglutide sourcing brief for recurring GLP-1 catalog supply

For qualified buyers, Semaglutide should be evaluated through identity, commercial fit, and document readiness. Identity fields include CAS 910463-68-2, formula C187H291N45O59, 4114 Da molecular weight. The sourcing checklist is SKU coverage such as 10mg*10vials · 15mg*10vials · 20mg*10vials · 2mg*10vials · 3 more sizes, ≥99%, batch-file access, MOQ, lead time, and repeat-order suitability.

Compare category

Quick sourcing answer

Identity
CAS 910463-68-2; formula C187H291N45O59; public label references list semaglutide as a GLP-1 analog with molecular weight 4113.58 g/mol.
Procurement fit
Built for laboratories, distributors, and qualified sourcing teams comparing GLP-1 catalog coverage, repeat-batch continuity, and bulk quote readiness.
Document review
Request current COA, HPLC chromatogram, MS identity support, SDS, storage notes, salt or counter-ion context, and batch-specific label details before approval.
SKU planning
Active catalog coverage includes 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg, and 50 mg x 10-vial options with order-wide tier pricing.

Procurement checks

  • Confirm CAS 910463-68-2, formula C187H291N45O59, molecular-weight reference, and current batch files.
  • Compare 2 mg to 50 mg x 10-vial SKU options, minimum order, and order-wide tier pricing for repeat purchasing.
  • Request batch COA, HPLC, MS, SDS, storage notes, salt or counter-ion context, and label details for procurement records.
  • Separate catalog ordering, distributor replenishment, and OEM/private-label requirements before requesting a quote.

Buyer comparison notes

Compared with Tirzepatide
Buyers usually compare GLP-1 vs GLP-1/GIP category fit, fill ladder, purity files, price tier, and lead-time stability.
Compared with Retatrutide
Review GLP-1 vs broader GLP-1/GIP/GCG category demand, identity support, SKU plan, and documentation requirements across the metabolic category.
Search-intent handling
Reconstitution or dosing searches are handled as vial-size, storage, and document questions, not as personal-use guidance.

Technical procurement review

Molecular identity and public-reference context

Semaglutide should be reviewed as a named GLP-1 analog record, not as a generic vial label. Public label data describes a GLP-1 receptor agonist with C187H291N45O59 formula, 4113.58 g/mol molecular weight, albumin-binding protraction through a position-26 lysine modification with a spacer and C18 fatty di-acid, and stabilization against DPP-4 degradation. Procurement teams should use those public identity anchors as a reference layer, then confirm the supplier record, CAS, formula, SKU, and batch documents before comparison.

What buyers should compare before quote approval

A useful Semaglutide quote review connects chemistry, documents, and commercial terms. Compare CAS 910463-68-2, molecular formula, molecular-weight reference, purity basis, fill size, net peptide content, HPLC purity, MS identity, salt or counter-ion notes when disclosed, storage guidance, lead time, MOQ, and whether the same document standard can be repeated across future batches.

Semaglutide vs Tirzepatide vs Retatrutide sourcing angle

Semaglutide demand often overlaps with Tirzepatide and Retatrutide searches, but a buyer should separate category interest from sourcing evidence. Semaglutide is typically reviewed as a GLP-1 material; Tirzepatide as a GLP-1/GIP category record; Retatrutide as a broader GLP-1/GIP/GCG comparison point. The B2B decision is driven by identity, SKU coverage, document availability, order tier, destination requirements, and repeat-batch planning.

Repeat catalog supply and private-label planning

For distributors, Semaglutide is often part of a recurring GLP-1 catalog plan rather than a one-time sample request. Buyers should define the target vial ladder, label or packaging requirements, acceptable document packet, replenishment cadence, and whether the order stays within standard catalog supply or moves into OEM/private-label review.

Public identity anchors

PubChem CID 56843331Public compound identity record for Semaglutide.FDA label referencePublic label description lists formula, molecular weight, and GLP-1 analog context.DailyMed label indexNLM label listings for semaglutide-containing drug products.

Request checklist

  • Current SKU size and fill target
  • COA, HPLC, MS, and SDS document needs
  • MOQ, order tier, and repeat-order estimate
  • Storage, transport, and destination-market requirements

Useful next pages

Metabolic & GLP-1 categoryCompare GLP-1, GIP, GCG, and metabolic-pathway sourcing options.Quality & COA supportReview the document request flow before procurement.Facility & processSee how sourcing, batch review, packing, and shipment support fit together.

Quality documentation

COA, HPLC, and MS support for this product.

Batch document coverage is summarized below. Qualified buyer packets are matched by product name, SKU, purchase-list item, and confirmed lot during QA review.

COA

Batch-specific certificate available for qualified buyer review.

HPLC

Purity documentation available for every product.

MS

Molecular identity confirmation available on request.

SDS

Safety and handling documents available for procurement review.

Document packet

Document coverage for qualified buyer review

COA

Batch-specific certificate of analysis for buyer review.

HPLC chromatogram

Purity chromatogram available for every product request.

Mass-spec identity

Identity support packet can be matched to the requested SKU.

Residual solvent / counter-ion

Provided when available or required for procurement review.

SDS / MSDS

Safety and handling document available for operational review.

Stability or release support

Shared when relevant to the requested batch or OEM workflow.

Molecular & Structure

CAS
910463-68-2
Molecular formula
C187H291N45O59
Molecular weight
4114

Research Evidence & Regulatory Notes

PeptideSource keeps public identity references and supplier-side documents attached to Semaglutide as sourcing support. Qualified buyers can request the current COA, HPLC chromatogram, MS identity support, SDS, storage guidance, and applicable batch context before quote approval.

Public Sources & References

Europe PMCeuropepmc.org · 5 recordsClinicalTrials.govclinicaltrials.gov · 3 recordsPubChempubchem.ncbi.nlm.nih.govA Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023)ClinicalTrials.govEffects of Semaglutide on Intracranial Blood Flow and Brain-Barrier Permeability in Type-2 DiabetesClinicalTrials.govAcute Subcutaneous SemaglutidE in Acute Ischemic sTrokeClinicalTrials.govCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.Buse JB, Bajaj HS, Dalskov SM, Donaldson L, Hansen Duus HH, Fabricius TW, Haluzík M, Lingvay I, Pedersen SD, Pratley RE, Jain AB, REIMAGINE 2 study group. · 2026 · Europe PMCSemaglutide2006 · Europe PMCSemaglutide, at a dose that produces modest weight loss, induces mild suppression of bone remodeling in healthy control rats and those with chronic kidney disease.Allen MR, Metzger CE, Chen NX, Tinsley IC, DiMarchi RD, O'Neill K, Matter EK, Moe SM. · 2026 · Europe PMCSemaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.Plotkin M, Ivkovic M, Smith I, Rathor N, Chowdhury R, Hodkinson A, Kushner RF. · 2026 · Europe PMCSafety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.Klein KR, Menacher A, Buse JB, Mann JFE, Tuttle KR, Kvist K, Andersen MR, Mayrdorfer M, Lingvay I. · 2026 · Europe PMC

Buyer questions

Common sourcing questions

What makes Semaglutide different from a generic peptide listing?

Semaglutide is grouped for metabolic and incretin-pathway research-material sourcing, so the useful procurement review includes incretin, amylin, metabolic-pathway, SKU ladder, and batch-file readiness in addition to identity fields, SKU size, MOQ, and quote terms.

Which quality documents can be requested for Semaglutide?

Qualified buyers can request COA, HPLC purity support, MS identity context, SDS, storage notes, and batch-specific information when available for the quoted SKU.

How should buyers compare Semaglutide before approving a quote?

Compare identity fields, category-specific review points, purity basis, SKU size, MOQ, lead time, tier pricing, storage expectations, and document packet readiness.

Does this page provide use instructions for Semaglutide?

No. The page is written for qualified B2B research-material sourcing, supplier evaluation, and document review only.

Can PeptideSource support bulk or repeat-order review for Semaglutide?

Yes. Buyers can share target SKU sizes, quantity expectations, document requirements, destination needs, and repeat-order plans for B2B quote review.

Which identity fields define Semaglutide for PeptideSource sourcing review?

Semaglutide is reviewed against CAS 910463-68-2, formula C187H291N45O59, 4114 Da. The next check is the current batch packet, including COA, HPLC chromatogram, MS or identity support, and any label or storage notes needed for a procurement file.

How should Semaglutide searches around cas 910463-68-2, formula, and glp-1 identity review be used for sourcing?

CAS 910463-68-2, formula, and GLP-1 identity review is treated as search context, not as a protocol or outcome claim. PeptideSource people usually check CAS 910463-68-2, formula C187H291N45O59, 4114 Da, SKU coverage such as 10mg*10vials, purity basis, COA/HPLC/MS support, storage notes, and batch-document availability before comparing suppliers.

How should Semaglutide searches around coa, hplc/ms, salt form, and batch document review be used for sourcing?

COA, HPLC/MS, salt form, and batch document review is treated as search context, not as a protocol or outcome claim. PeptideSource people usually check CAS 910463-68-2, formula C187H291N45O59, 4114 Da, SKU coverage such as 10mg*10vials, purity basis, COA/HPLC/MS support, storage notes, and batch-document availability before comparing suppliers.

How does PeptideSource handle COA, HPLC, and MS requests for Semaglutide?

Send the product name, SKU, or intended purchase-list line and the support team will match available COA, HPLC chromatogram, MS identity support, SDS, storage notes, and related batch context. Documents are shared for qualified buyer, sourcing, and procurement review.

How should Semaglutide SKU size and fill options be scoped?

Semaglutide has catalog coverage that includes 10mg*10vials. Buyers should compare the full SKU ladder, minimum order, sales unit, and order-wide tier pricing before deciding whether catalog supply, bulk replenishment, or custom fill review is needed.

How is Semaglutide compared inside a GLP-1 or metabolic sourcing list?

The comparison is built around molecular identity, CAS record when available, vial or fill ladder, purity basis, salt or counter-ion notes, lead time, tier pricing, and batch-file readiness. Public outcome language is not used as procurement evidence.

Why do searches mention Semaglutide dosage, route, or reconstitution terms?

Those search terms usually point to public discussions about vial strength, concentration math, handling, and route-of-use language. PeptideSource treats them as search context only. The sourcing review stays with SKU size, purity basis, COA/HPLC/MS support, storage notes, and batch-label information for the buyer's own compliance process.

Research Center

Procurement comparison and document guides

View all guides
Supplier evaluationWhere to Buy Research Peptides with COA DocumentationCOA reviewHow to Read a Peptide COA for B2B Research SourcingSpecification comparisonSemaglutide vs Tirzepatide vs Retatrutide: Specification Comparison

Technical Library

Long-form quality and sourcing context

View library
GLP-1 research trendsGLP-1 Peptide Research Trends 2026: Tirzepatide, Semaglutide & BeyondQuality documentationPeptide Purity Grades Explained: HPLC vs. Prep-HPLCProduct comparisonTirzepatide vs. Semaglutide: Research Comparison

Related products

More in Metabolic & GLP-1

Browse category
Tirzepatide2023788-19-2RetatrutideLY-3437943Cagrilintide1415456-99-3